Filing summary
TransCode Therapeutics, Inc. (Nasdaq: RNAZ) filed this Form 8-K on September 28, 2026. The filing reports an event, not a financial reporting period.
Business context and event
The company announced updated clinical data from its Phase 1a dose clinical trial of TTX-MC138. The 8-K incorporates a September 28, 2026 press release as Exhibit 99.1, but the press release’s data and details are not included in the provided filing text.
Financial metrics and changes
The filing provides no revenue, profit, cash flow, margin, debt, liquidity, or other financial metrics, and no comparable-period financial results.
Outlook, risks, and unusual items
No guidance, financial outlook, management commentary beyond the clinical-data announcement, or specific risks or contingencies are described in the provided text.
Key facts to verify
- Review Exhibit 99.1 for the actual TTX-MC138 clinical data, trial details, and any stated limitations or safety findings.
- Check subsequent company filings for additional clinical updates or financial information.